Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT03123588 |
| Title | Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272) |
| Recruitment | Terminated |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Incyte Corporation |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA |